Value Based Pricing - A New Concept in Pharmaceuticals

Value Based Pricing - A New Concept in Pharmaceuticals

In the face of stagnant healthcare budgets and ever-growing demand for care, value-based pricing has real potential to bring value to patients.

1000
Pharma

KPMG in Sri Lanka with support from it’s global network have introduced the 'Healthcare and Life Sciences' department under the patronage of Dulitha Perera. The main focus lies on providing solutions for both public and private sector healthcare institutions.

The article on value based pricing in pharmaceuticals is believed to bring a revolutionary change in the Sri Lankan pharmaceutical industry as demonstrated by studies conducted by KPMG all over the world. External challenges are forcing pharmaceutical companies to change business models from ‘sales push’ towards a more value-based model. Within a value based pricing arrangement, risk is shared between pharma companies and payers, which means all parties should focus on appropriateness of use and on outcomes.

© 2024 KPMG, a Sri Lankan partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.


For more detail about the structure of the KPMG global organization please visit https://kpmg.com/governance.

Connect with us